C.D.C. Recommends 2 Covid Vaccines for under 5s
95.9% of children aged 8 to 11 years had antibodies against SARS-CoV-2
Coronavirus (COVID-19) Update: FDA Authorizes Moderna and Pfizer-BioNTech COVID-19 Vaccines for Children Down to 6 Months of Age
Risks of Myocarditis and Pericarditis
The FDA and CDC safety surveillance systems have previously identified increased risks of myocarditis and pericarditis following vaccination with the Moderna COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine, particularly following the second dose.
The observed risk is highest in,
males 18 through 24 years of age for the Moderna
males 12 through 17 years of age for the Pfizer-BioNTech COVID-19 Vaccine.
most cases of myocarditis associated with the Moderna and Pfizer-BioNTech COVID-19 vaccines are characterized by rapid resolution of symptoms
with no impact on quality of life reported by most patients who were contacted for follow-up at 90 days or more after reporting myocarditis.
Moderna for ages 6 months through 5 years
Pfizer-BioNTech ages 6 months through 4 years
Dr. Rochelle P. Walensky, the C.D.C.’s director
All children 6 months and older,
including those who have already been infected with the coronavirus,
should get a Covid vaccine
Together, with science leading the charge, we have taken another important step forward in our nation’s fight against Covid-19
We know millions of parents and caregivers are eager to get their young children vaccinated, and with today’s decision, they can
Albert Bourla, Chairman and Chief Executive Officer, Pfizer
We know many parents in the U.S. have been eagerly awaiting an authorized vaccine for their children under 5 and we are proud to now offer them a vaccine option with a favorable safety profile
Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose
Vaccine efficacy was 80.3% in children 6 months to under 5 years of age.
N = 1,678 had 3 doses, (omicron times)
This descriptive analysis was based on 10 symptomatic COVID-19 cases identified from seven days after the third dose and accrued as of April 29, 2022.
(3 in the vaccine group, 7 in the placebo group)
The trial protocol specifies a formal analysis will be performed when at least 21 cases have accrued from seven days after the third dose.
Final vaccine efficacy data will be shared once available.
Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age
MODERNA ANNOUNCES ITS COVID-19 VACCINE PHASE 2/3 STUDY IN CHILDREN 6 MONTHS TO UNDER 6 YEARS HAS SUCCESSFULLY MET ITS PRIMARY ENDPOINT
6 months to 2 years, n = 2,500 enrolled
2 to under 6, n = 4,200 enrolled
Rates of fever post vaccine, greater than 38
6 months to 2 years, 17%
2 years to under 6, 14.6%
6 to 12 years, 23.9%
Similar antibody response to in 18- to 25-year-olds
6 months to 2 years, 43.7%
2 to under 6 years, 37.5%
Kaiser Family Foundation survey
Plan to get under 5s vaccinated, 18%
Definitely not, 27%
Tom Inglesby, Johns Hopkins Center for Health Security, Bloomberg School of Public Health
There’s a lot of information and trust building that needs to happen
Hopefully, with time, people will have increasing confidence that it’s both effective and safe
Neither vaccine was tested against BA.4 and BA.5
(exceptional immune escape)
Peter Hotez, molecular virologist, National School of Tropical Medicine at Baylor College of Medicine, Houston
The pediatric vaccines, won’t hold up that well in protecting against infection by the new subvariants
But they will still be very effective in preventing children from going to the hospital or the intensive care unit
ACIP Committee Members